Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon, Taiho to Invest US$30 Million Each in Remiges BioPharma Fund
July 25, 2014
- Ono, BMS Announce Strategic Alliance for 5 Immuno-Oncology Products
July 25, 2014
- R-Tech Ueno Files for Orphan Drug Designation for Unoprostone Isopropyl for Retinitis Pigmentosa
July 25, 2014
- With Series of Antidiabetics on the Way, Prioritization Will Be a Challenge: Lilly Japan Diabetes Head
July 25, 2014
- Astellas Gears Up to Accelerate R&D
July 24, 2014
- Maruho Seeks Approval of Antibacterial Drug Ozenoxacin in Japan
July 24, 2014
- Japan Antidepressant Market Valued at 151 Billion Yen in 2022
July 24, 2014
- Jiangsu Hengrui Medicine of China Establishes Japanese Subsidiary; Aims for Sales of 10 Billion Yen by 2022
July 24, 2014
- Takeda, ASKA to Cease Seltouch Marketing by Late September
July 24, 2014
- Kyorin Licenses OAB Treatment Vibegron from Merck
July 24, 2014
- Research Lab for High-Value Generics Goes Live: Kobayashi Kako
July 23, 2014
- Terumo US Unit Opens New Plant in Vietnam
July 23, 2014
- Tatsumi Kagaku Adjusts Supply of Nu-lotan Generic
July 22, 2014
- Disclosure of Payments from Drug Makers to Doctors Delayed
July 22, 2014
- Chugai Obtains Marketing Rights for Antiemetic NEPA in the UK, Ireland from Helsinn Group
July 22, 2014
- Ethical Drug Sales Down 6.5% in May: Crecon Report
July 18, 2014
- Novartis, Maruho Form Sales Tie-Up for Psoriasis Agent
July 18, 2014
- Carna Shooting for 1st Licensing Deal on Kinase Inhibitor in 2014
July 18, 2014
- Ono to Target Cancers with Unmet Medical Needs: President
July 18, 2014
- AnGes MG Initiates Development of Next Generation Collategene
July 18, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…